UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2022.

Commission File Number: **001-40673**

Cybin Inc.
(Exact Name of Registrant as Specified in Charter)

100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

INCORPORATION BY REFERENCE

Exhibit 99.1 of this Form 6-K of Cybin Inc. (the "Company") is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-259994) of the Company, as amended or supplemented.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CYBIN INC.
(Registrant)

Date: June 2, 2022		By:	*/s/ Doug Drysdale*
		Name:	Doug Drysdale
		Title:	Chief Executive Officer

EXHIBIT INDEX

99.1	News Release dated June 2, 2022

Cybin Announces Publication in *Frontiers in Psychology* Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy

TORONTO, CANADA – June 2, 2022 – Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("**Cybin**" or the "**Company**"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", is pleased to announce the publication of a peer-reviewed article introducing EMBARK, a model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines.

"It's a pleasure to see our work published in this respected journal. In developing EMBARK, we looked at 17 models of psychedelic-assisted psychotherapy, and we noticed that many are missing critical elements: a focus on ethics, on human relationships, on the body as a site of somatic healing, and on evidence-based practices. We designed EMBARK to overcome some of these limitations as an integrative model of psychedelic therapy. We'd like to honor the contributions of many teachers and leaders in the field who have helped chart this course," said Alex Belser, PhD, EMBARK's co-creator and Cybin's Chief Clinical Officer.

The article was published on June 2, 2022 in the peer-reviewed journal *Frontiers in Psychology* and is titled, "Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model." Written by EMBARK's co-creators, Bill Brennan, PhD and Alex Belser, PhD, Cybin's Chief Clinical Officer, the article provides a detailed overview of EMBARK to the academic and clinical communities. *Frontiers in Psychology* is the largest journal in the field of psychology.

"We are excited to present our model to the field in a way that highlights its thoughtfulness and responsiveness to current concerns in psychedelic research. We have listened carefully to what has worked, and what has been found lacking, and offer EMBARK as an innovative step forward," said Bill Brennan, PhD, EMBARK's co-creator.

The article also provides an overview of EMBARK's six clinical domains (**E**xistential-Spiritual, **M**indfulness, **B**ody Aware, **A**ffective-Cognitive, **R**elational, and **K**eeping Momentum) and highlights the strengths and limitations of existing psychedelic-assisted psychotherapy approaches and evidence-based therapies. The article is the first of a series of publications aimed at presenting EMBARK as an open-source model of practice and training for therapists and facilitators supporting psychedelic-based treatments.

“If psychedelics are ever to be integrated into modern clinical medicine, the usage protocols are as important as the medicines themselves. In this respect Cybin is a leader. Cybin has assembled a faculty of top-notch therapists to lead its EMBARK program, which incorporates a multi-dimensional approach to therapies that enable them to be tailored to a variety of patient needs. With the implementation of EMBARK, Cybin is setting high standards for the future of psychedelic therapy,” said Dennis J. McKenna, Ph.D., Founding Board Member of Heffter Research Institute and President and Principal Founder of McKenna Academy of Natural Philosophy.

The article can be accessed online here.

Cybin’s upcoming clinical trials evaluating the Company’s proprietary psychedelic-based molecules CYB003 and CYB004 for treating major depressive disorder, alcohol use disorder, and anxiety disorders will use EMBARK to support study participants.

About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the Company’s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens to potentially treat psychiatric disorders.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company's management's discussion and analysis for the period ended December 31, 2021 and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.

Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Investor & Media Contact:
Leah Gibson
Vice President, Investor Relations & Strategic Communications
Cybin Inc.
irteam@cybin.com -or- media@cybin.com